At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed diffuse large B-cell non-Hodgkin's lymphoma (including B-cell diffuse large cell, immunoblastic, mediastinal, T-cell/histiocyte-rich, anaplastic large B-cell, intravascular, or lymphomatoid granulomatosis variants)
- ✓Relapsed or refractory disease after at least 1 prior chemotherapy regimen with new lesions, ≥50% increase in size of previously involved sites, or progressive disease during/at end of therapy
- ✓CD20-positive disease confirmed by immunohistochemistry
- ✓Bidimensionally measurable disease with at least 1 lesion ≥2.0 cm on CT scan
- ✕Transformed lymphoma from indolent to aggressive histology
- ✕HIV- or AIDS-related lymphoma
- ✕Hypocellular bone marrow or marked reduction in bone marrow precursors (granulocytic, megakaryocytic, or erythroid cell lines)
- ✕CNS lymphoma
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Zevalin And Rituxan For The Treatment Of Relapsed Or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
In Brief
A Phase 2 clinical trial evaluating rituximab, cytarabine, and 2 other interventions for Lymphoma. Completed, enrolled 25 participants across 2 sites.
Detailed Summary
RATIONALE: Monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan and rituximab, can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Combining yttrium Y 90 ibritumomab tiuxetan with rituximab may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining yttrium Y 90 Ibritumomab tiuxetan with rituximab in treating patients who have relapsed or refractory diffuse large B-cell non-Hodgkin's lymphoma.
Study Details
Timeline
Interventions
to be used for CNS prophylaxis
to be used as CNS prophylaxis